Pictet Asset Management (UK)’s Bionano Genomics BNGO Stock Holding History

Pictet Asset Management (UK)’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$148K	Buy	+34	New	+$134K	﹤0.01%	1667

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Pictet Asset Management (UK)'s BNGO Position: Q2 2021 in Review

Pictet Asset Management (UK) opened a new position in Bionano Genomics (BNGO) in Q2 2021: 34 shares worth $148K. The stake represents ﹤0.01% of the portfolio and ranks #1667 among its holdings.

152 funds tracked by Wall St. Rank hold BNGO as of Q2 2021.

Pictet Asset Management (UK) held 34 shares of Bionano Genomics worth $148K as of Q2 2021.
Bionano Genomics was a new Pictet Asset Management (UK) position in Q2 2021.
Bionano Genomics made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1667 holding.
152 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.